T1	Participants 99 121	breast cancer patients
T2	Participants 733 791	cancer patients receiving chemotherapy and/or radiotherapy
T3	Participants 890 966	fifty-eight breast cancer patients who received chemotherapy or radiotherapy
T4	Participants 1089 1137	patients receiving either an RG-CMH or a placebo
T5	Participants 1407 1419	RG-CMH group
T6	Participants 1576 1589	placebo group
